See the DrugPatentWatch profile for Xelstrym
The question about a generic for Xelstrym is likely related to its patent status and potential market entry for biosimilar versions. Xelstrym is the brand name for an injection containing adalimumab-abda, a biosimilar to Humira [1].
When does Xelstrym's patent protection end?
As Xelstrym is a biosimilar, its market exclusivity is tied to the patents of the reference biologic, Humira (adalimumab) [2]. Patents for Humira have been the subject of extensive litigation, and various patents have expired or been invalidated at different times. This complex patent landscape has allowed for the introduction of multiple adalimumab biosimilars [3]. Information on specific patent expiry dates for adalimumab can be found on resources like DrugPatentWatch.com [4].
How do Xelstrym and Humira compare?
Xelstrym is a biosimilar to Humira [1]. Biosimilars are approved by regulatory agencies like the FDA and are highly similar to an already approved reference biologic, meaning they have no clinically meaningful differences in terms of safety, purity, and potency [5]. They are not considered generics in the same way as small-molecule drugs are; rather, they are highly similar versions of complex biologic medicines [6].
Who makes Xelstrym?
Xelstrym is manufactured by Fresenius Kabi [1].
What conditions does Xelstrym treat?
Xelstrym, like its reference product Humira, is indicated for the treatment of several inflammatory conditions. These include moderate to severe rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, and plaque psoriasis [1].
What is the price of Xelstrym?
Pricing for biosimilars, including Xelstrym, is generally expected to be lower than the reference biologic. However, the exact price can vary based on the manufacturer, dosage, and insurance coverage. Further details on pricing would typically be available through healthcare providers or pharmacy benefit managers.
What are the potential risks and side effects of Xelstrym?
As a biosimilar to Humira, Xelstrym carries similar potential risks and side effects. These can include serious infections, allergic reactions, and an increased risk of certain cancers. Patients should discuss these risks with their healthcare provider [7].
Are there other adalimumab biosimilars available?
Yes, several other biosimilars to adalimumab have been approved and are available in the market. These include products from manufacturers such as Amgen (Amjevita), Sandoz (Hyrimoz), and Boehringer Ingelheim (Cyltezo) [3].
Sources:
1. https://www.drugpatentwatch.com/
2. https://www.drugpatentwatch.com/
3. https://www.drugpatentwatch.com/
4. https://www.drugpatentwatch.com/
5. https://www.fda.gov/
6. https://www.fda.gov/
7. https://www.drugpatentwatch.com/